| Item Type | Name |
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Antineoplastic Agents, Hormonal
|
|
Concept
|
Antineoplastic Agents, Phytogenic
|
|
Academic Article
|
Phase I study of amonafide dosing based on acetylator phenotype.
|
|
Academic Article
|
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
|
|
Academic Article
|
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.
|
|
Academic Article
|
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
|
|
Academic Article
|
Prospects for fertility after cancer chemotherapy.
|
|
Academic Article
|
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
|
|
Academic Article
|
Antifolates: the next generation.
|
|
Academic Article
|
O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings.
|
|
Academic Article
|
Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.
|
|
Academic Article
|
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
|
|
Academic Article
|
End points in cancer clinical trials and the drug approval process.
|
|
Academic Article
|
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
|
|
Academic Article
|
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
|
|
Academic Article
|
Pharmacology and clinical status of capecitabine.
|
|
Academic Article
|
Antineoplastic drugs administered during pregnancy.
|
|
Academic Article
|
Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
|
|
Academic Article
|
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
|
|
Academic Article
|
Silence is golden: gene hypermethylation and survival in large-cell lymphoma.
|
|
Academic Article
|
Paradoxical relationship between acetylator phenotype and amonafide toxicity.
|
|
Academic Article
|
Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?
|
|
Academic Article
|
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
|
|
Academic Article
|
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
|
|
Academic Article
|
3rd EORTC-NCI International Meeting on Cancer Molecular Markers: From Discovery to Clinical Practice.
|
|
Academic Article
|
The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics).
|
|
Academic Article
|
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue.
|
|
Academic Article
|
Are targeted therapies really targeted?
|
|
Academic Article
|
Personalizing cancer care: American Society of Clinical Oncology presidential address 2009.
|
|
Academic Article
|
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
|
|
Academic Article
|
Refocusing the war on cancer: the critical role of personalized treatment.
|
|
Academic Article
|
Personalized medicine in oncology: the future is now.
|
|
Academic Article
|
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
|
|
Academic Article
|
Commentary: tackling the challenges of developing targeted therapies for cancer.
|
|
Academic Article
|
Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications.
|
|
Academic Article
|
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
|
|
Academic Article
|
Male fertility following cancer chemotherapy.
|
|
Academic Article
|
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
|
|
Academic Article
|
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.
|
|
Academic Article
|
How not to treat cancer.
|
|
Academic Article
|
Chemotherapy for testicular cancer: current status of the National Cancer Institute Combined Modality Trial.
|
|
Academic Article
|
Data submission standards and evidence requirements.
|
|
Academic Article
|
Effects of cancer treatment on the reproductive system.
|
|
Academic Article
|
Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.
|
|
Academic Article
|
GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy.
|
|
Academic Article
|
Gonadal dysfunction in patients receiving chemotherapy for cancer.
|
|
Academic Article
|
Renal and metabolic toxicities of cancer chemotherapy.
|
|
Academic Article
|
Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
|
|
Academic Article
|
Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans.
|
|
Academic Article
|
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward.
|
|
Academic Article
|
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics.
|
|
Academic Article
|
Ovarian function following radiation and chemotherapy for cancer.
|
|
Academic Article
|
Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease.
|
|
Academic Article
|
Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial.
|
|
Academic Article
|
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
|
|
Academic Article
|
Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
|
|
Academic Article
|
Phase I study of an oral formulation of ZD9331 administered daily for 28 days.
|
|
Academic Article
|
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
|
|
Academic Article
|
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.
|
|
Academic Article
|
Target practice: oncology drug development in the era of genomic medicine.
|
|
Academic Article
|
Pharmacodynamics in cancer therapy.
|
|
Academic Article
|
An accelerated pathway for targeted cancer therapies.
|
|
Academic Article
|
Role of randomized phase III trials in an era of effective targeted therapies.
|
|
Academic Article
|
The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of malignant lymphomas.
|
|
Academic Article
|
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
|
|
Academic Article
|
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
|
|
Academic Article
|
Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.
|
|
Academic Article
|
Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.
|
|
Academic Article
|
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.
|
|
Academic Article
|
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
|
|
Academic Article
|
Precision cancer medicine: the future is now, only better.
|
|
Academic Article
|
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.
|
|
Academic Article
|
Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.
|
|
Academic Article
|
Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis.
|
|
Academic Article
|
Response.
|
|
Academic Article
|
Implementing personalized cancer care.
|
|
Academic Article
|
Hans Christian Andersen and the Value of New Cancer Treatments.
|
|
Academic Article
|
Reevaluating the accelerated approval process for oncology drugs.
|
|
Academic Article
|
Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.
|
|
Academic Article
|
Moving from evaluation to value in cancer care.
|
|
Academic Article
|
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.
|
|
Academic Article
|
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary.
|
|
Academic Article
|
Improving evidence developed from population-level experience with targeted agents.
|
|
Academic Article
|
Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement.
|
|
Academic Article
|
Accelerating anticancer drug development - opportunities and trade-offs.
|
|
Academic Article
|
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.
|
|
Academic Article
|
Gains Against Cancer, But Enter 'Financial Toxicity'.
|
|
Academic Article
|
American Society of Clinical Oncology Statement: Biosimilars in Oncology.
|
|
Academic Article
|
Modernizing Eligibility Criteria for Molecularly Driven Trials.
|
|
Academic Article
|
Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.
|
|
Academic Article
|
Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies.
|
|
Academic Article
|
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
|
|
Academic Article
|
Reply to M. Hutton-Potts and A.M. Joshua.
|
|
Academic Article
|
Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
|
|
Academic Article
|
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
|
|
Academic Article
|
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
|
|
Academic Article
|
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
|
|
Academic Article
|
Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.
|
|
Concept
|
Antineoplastic Agents, Immunological
|
|
Grant
|
CANCER AND LEUKEMIA GROUP B--PET COMMITTEE
|
|
Academic Article
|
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.
|
|
Academic Article
|
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
|
|
Academic Article
|
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
|
|
Academic Article
|
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
|
|
Academic Article
|
Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
|
|
Academic Article
|
Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
|